References
Tefferi A, Silverstein MN, Petitt RM, Mesa RA, Solberg LA Jr (1997) Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of action, efficacy, toxicity, current indications. Semin Thromb Hemost 23:379–383
Birgegard G, Bjorkholm M, Kutti J, Larfars G, Lofvenberg E, Markevarn B, Merup M, Palmblad J, Mauritzson N, Westin J, Samuelsson J (2004) Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders. Haematologica 89(5):520–527
Steurer M, Gastl G, Jedrzejczak WW, Pytlik R, Lin W, Schlogl E, Gisslinger H (2004) Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile. Cancer 101(10):2239–2246
Data on file (Prod Info Agrylin(TM), (1999))
Wright CA, Tefferi AA (2001) A single institutional experience with 43 pregnancies in essential thrombocythemia. Eur J Haematol 66:152–159
Doubek M, Brychtova Y, Doubek R, Janku P, Mayer J (2004) Anagrelide therapy in pregnancy: report of a case of essential thrombocythemia. Ann Hematol 83:726–727
Jurgens DJ, Moreno-Aspitia A, Tefferi A (2004) Anagrelide-associated cardiomyopathy in polycythemia vera and essential thrombocythemia. Haematologica 89(11):1394–1395
Green A, Campbell P, Buck G, Wheatley K, East C, Bareford D, Wilkins B, Walt JV, Reilly J, Harrison C (2004) The Medical Research Council PT1 trial in essential thrombocythemia. Blood 104(11):5a–6a. Abstract 6
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
AlKindi, S., Dennison, D. & Pathare, A. Successful outcome with anagrelide in pregnancy. Ann Hematol 84, 758–759 (2005). https://doi.org/10.1007/s00277-005-1059-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-005-1059-8